Scotia Capital Inc. Has $4.26 Million Stock Holdings in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)

Scotia Capital Inc. decreased its stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 0.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,391,719 shares of the company’s stock after selling 4,562 shares during the quarter. Scotia Capital Inc.’s holdings in Eupraxia Pharmaceuticals were worth $4,259,000 as of its most recent SEC filing.

Separately, Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $37,000.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They set a “buy” rating and a $12.00 price objective on the stock.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX opened at $3.03 on Friday. The company has a market cap of $108.44 million and a PE ratio of -4.20. The firm has a 50-day moving average of $3.54 and a 200-day moving average of $3.17. Eupraxia Pharmaceuticals Inc. has a one year low of $2.20 and a one year high of $4.48.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.